Press release
United Therapeutics to Present New Data at CHEST Annual Meeting 2021
A total of 10 abstracts reinforce United Therapeutics' commitment to advancing research in pulmonary hypertension Additional subgroup analyses evaluate data
About this update from United Therapeutics Corporation
[{"type":"text","content":"A total of 10 abstracts reinforce United Therapeutics' commitment to advancing research in pulmonary hypertension\n Additional subgroup analyses evaluate data from the Tyvaso® INCREASE study in PH-ILD\n Additional new data evaluate the pharmacokinetics of Tyvaso DPI™ from the BREEZE study\n\n\nSILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 11, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced new data on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented as posters at CHEST 2021, the annual meeting of the American College of Chest Physicians, which will be held virtually October 17-20. United Therapeutics and its collaborators are presenting a total of 10 abstracts across a broad range of studies in PAH and PH-ILD, including pharmacokinetic (PK) data from the BREEZE study of Tyvaso DPI™. \n\"Our decades-long commitment to pulmonary hypertension has yielded favorable results, and the data we're presenting at CHEST 2021 show the potential for our research to help transform patients' lives,\" said Gil Golden, M.D., Ph.D., Chief Medical Officer of United Therapeutics. \"We will continue our work to evolve the standards of care in pulmonary hypertension to help improve the quality of life for patients living with this condition.\"\nThe CHEST meeting will feature a poster detailing PK data from the BREEZE study of Tyvaso DPI in patients with PAH. The BREEZE study enrolled 51 subjects on a stable regimen of Tyvaso who were transitioned to Tyvaso DPI at a corresponding treprostinil dose. The primary objective of the study was to evaluate the safety and tolerability of Tyvaso DPI during a three-week treatment phase in PAH patients previously treated with Tyvaso Inhalation Solution. Secondary objectives of the study included changes in six-minute walk distance, device preference and satisfaction as evaluated through the Preference Questionnaire for Inhaled Treprostinil Devices, and patient-reported PAH symptoms and impact. Top line data showing the BREEZE study met its primary objective were released in January 2021, and detailed data on the primary and secondary objectives were presented in September 2021. PK data from a heal...